Stockscreener 앱 받기
13.06
1.24%
0.1658
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - Capital.com
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance
EYPT: DURAVYU phase III trials show strong progress, safety, and reduced treatment burden, with key data due soon - TradingView
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - minichart.com.sg
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Yahoo Finance
Eyepoint files complaint against Ocular Therapeutix in Middlesex County Superior Court - marketscreener.com
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - Sahm
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint Pharmaceuticals Q4 2025 earnings preview - msn.com
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock By Investing.com - Investing.com Australia
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com
Family trust of EyePoint (EYPT) CEO acquires 1,500 company shares - Stock Titan
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks
Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada
Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com
EyePoint (EYPT) Issues Stock Options to New Employees as Hiring Incentives - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals - Intellectia AI
Suvretta Capital Management LLC Sells 611,376 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1%Here's Why - MarketBeat
Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
1.44%
자본화:
|
볼륨(24시간):